On February 28, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Targeted Anticancer Therapies (TAT) Congress 2022 being held virtually March 7-8, 2022 (Press release, Spectrum Pharmaceuticals, FEB 28, 2022, View Source [SID1234609148]). Details of the presentation are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
Speaker: Sophie Sun, M.D., FRCPC
Session Type: Mini oral session
Date and Time: March 7, 2022 at 5:50 p.m. CET / 11:50 a.m. ET
Presentation Number: 26MO
The presentation will be published online on the ESMO (Free ESMO Whitepaper) website at 12 p.m. CET / 6 a.m. ET on March 7, 2022. It will also be available on the Spectrum Pharmaceuticals website after the presentation at View Source